EZH2 inhibitor combination therapies
AssigneePfizer Inc.
InventorsManfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
Life of this patent
Estimating the term…
Abstract
This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
Claims8
A method of treating small cell lung cancer (SCLC) in a subject comprising a first step of administering to the subject a combination therapy which comprises 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one, and a platinum based antineoplastic agent, and a second step of administering to the subject a monotherapy of 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one, wherein the second step does not include administering to the subject said platinum based antineoplastic agent.
Dependencies are inferred from the claim text.